Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/013890external-prioritypatent/WO2006113360A2/en
Application filed by Chiron CorpfiledCriticalChiron Corp
Publication of NO20075898LpublicationCriticalpatent/NO20075898L/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Fremgangsmåter for profylaktisk eller terapeutisk å behandle alvorlig lungebetennelse som involverer å gi vevsfaktor pathway inhibitor (TFPI) eller en TFPI analog til pasienter som lider av eller som er i risikosonen for å utvikle denne tilstand. Fremgangsmåten involverer anvendelsen av kontinuerlig intravenøs infusjon av TFPI eller en TFPI analog helst ved lave doser for å unngå alvorlige bieffekter.Methods for prophylactic or therapeutic treatment of severe pneumonia involving providing tissue factor pathway inhibitor (TFPI) or a TFPI analogue to patients suffering from or at risk of developing this condition. The method involves the use of continuous intravenous infusion of TFPI or a TFPI analogue preferably at low doses to avoid serious side effects.
NO20075898A2005-04-152007-11-15
Treatment of community acquired pneumonia by administration of tissue factor pathway inhibitor (TFPI)
NO20075898L
(en)
PS 04-10 KAEMPFEROL ATTENUATES MYOCARDIAL ISCHEMIC INJURY VIA INHIBITION OF MAPK SIGNALING PATHWAY IN EXPERIMENTAL MODEL OF MYOCARDIAL ISCHEMIA-REPERFUSION INJURY
MK-7 enhances expression of genes related to bone, enamel and dentin, and reduces the expression of genes related to apoptosis in developing murine molars
Legal Events
Date
Code
Title
Description
FC2A
Withdrawal, rejection or dismissal of laid open patent application